Business Context and Reporting Period
Company: Sharps Technology, Inc. (STSS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Sharps Technology is a medical device and pharmaceutical packaging company focused on safety syringes. The company commenced commercialization and recognized its first product revenues in the second quarter of 2025 following the acquisition of manufacturing capabilities and the execution of a supply agreement with Stericare Solutions, LLC.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | Balance Sheet (June 30, 2025) |
|---|---|---|---|
| Net Revenue | $222,722 | $222,722 | - |
| Gross Margin (Loss) | $(1,032,027) | $(1,032,027) | - |
| Net Income (Loss) | $3,559,307 | $5,488,141 | - |
| Operating Cash Flow | - | $(4,355,930) Used | - |
| Cash and Equivalents | - | - | $8,322,192 |
| Total Assets | - | - | $17,085,197 |
| Total Liabilities | - | - | $2,545,527 |
| Stockholders' Equity | - | - | $14,539,670 |
| Debt | - | - | $0 (Debt Free) |
Note: Net Income is significantly inflated by non-cash fair value adjustments on warrant liabilities.
Material Changes vs. Prior Period
- Revenue Generation: The company transitioned from $0 revenue in the prior year periods to $222,722 in Q2 2025, driven by initial shipments under a supply agreement with Stericare Solutions.
- Profitability Shift: The company reported a Net Income of $3.56 million for Q2 2025, compared to a Net Loss of $2.10 million in Q2 2024. This reversal is primarily due to a $6.47 million non-cash gain from the fair value adjustment of warrant liabilities, rather than operational profitability.
- Gross Margin: The company incurred a gross loss of $1.03 million. This was driven by a $730,086 inventory reserve established due to global tariff uncertainties and excess manufacturing costs ($199,000) prior to reaching planned production capacity.
- Liquidity: Cash balances increased from $864,041 at year-end 2024 to $8.32 million at June 30, 2025, following a $20 million equity offering in January 2025. The company used proceeds to repay $4.22 million in outstanding notes, leaving it debt-free.
- Capital Structure: A 1-for-300 reverse stock split was effective in April 2025. Outstanding shares increased to 1,023,214 following the offering and warrant exercises.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management states that while cash reserves are strong, they may not be sufficient to fund planned operations for the next 12 months without further financing or successful commercialization. Substantial doubt regarding the ability to continue as a going concern is disclosed.
- Unusual Items:
- Warrant Liability Gains: A $6.47 million gain (Q2) and $11.09 million gain (YTD) resulted from the remeasurement of warrant liabilities. This is a non-cash accounting adjustment.
- Inventory Reserve: A $730,086 charge was taken for inventory reserves due to market factors and tariffs.
- Legal Proceedings:
- Berler Lawsuit: Former CTO Barry Berler is suing for damages ($456,000) and claims to 50% of Series A Preferred Stock. The company intends to defend vigorously.
- Plastomold Lawsuit: Plastomold Industries is suing for $1.76 million regarding unpaid invoices and alleged defective machinery. The company has filed counterclaims.
- Outlook: The company is focused on fulfilling the Stericare order (520 million units over 5 years) and expanding production capacity in Hungary. R&D expenses decreased as focus shifted to manufacturing.
Investor Verification Checklist
- Non-Cash Income: Verify that the reported Net Income is driven by warrant liability adjustments ($6.5M gain) rather than core operations, which remain loss-making on a gross basis.
- Inventory Valuation: Review the $730k inventory reserve and the rationale regarding global tariffs and lower-of-cost-or-market adjustments.
- Liquidity Runway: Assess the $8.3M cash balance against the disclosed "substantial doubt" regarding the 12-month going concern status and the burn rate of ~$4.4M in operating cash over six months.
- Legal Exposure: Monitor the status of the Berler and Plastomold lawsuits, which involve claims totaling over $2.2 million.
- Revenue Sustainability: Confirm the execution of the Stericare supply agreement and the ability to scale production to meet the 40 million unit first-year commitment.